Skip to content
The Nexus
DossierENTITY

mRNA flu vaccine

Coverage of mRNA flu vaccine in the Nexus archive.

Earliest in view: May 21 · 21:53 UTCMost recent: Jun 19 · 12:49 UTC
Co-mentioned in this coverage
Modernaorganization4FDAorganization3older adultstopic1mFlusivatopic1FDA advisory panelorganization150 to 64topic165 and oldertopic1Vaccines and Related Biological Products Advisory Committeeorganization1Wellington Sunperson1Food and Drug Administrationorganization1MFLUSIVAtopic1Marty Makaryperson1
Recent coverage
  • HEALTHJun 19 · 12:49 UTCWGN9 CHICAGO
    FDA panel recommends mRNA flu vaccine for older adults

    An FDA panel recommended an mRNA flu vaccine for older adults. The final decision on Moderna’s flu shot is unclear due to the FDA lacking a permanent vaccine chief and commissioner.

  • HEALTHJun 18 · 22:31 UTCTHE HILL
    FDA panel recommends mRNA flu vaccine for older adults

    An FDA advisory panel unanimously recommended Moderna’s mRNA-based flu vaccine, mFlusiva, for approval in adults aged 50-64 and 65+. The panel voted 9-0 that the benefits outweigh the risks for the vaccine.

  • HEALTHJun 18 · 20:26 UTCSTAT NEWS
    STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

    An FDA advisory panel unanimously endorsed Moderna's mRNA flu vaccine, concluding its benefits outweigh risks for adults aged 50-64 and those 65+. The FDA may license it via traditional and accelerated pathways, with existing vaccines having used similar routes. Wellington Sun, a former FDA employee who later worked for Moderna, commented on accelerated pathways during the meeting.

  • HEALTHMay 21 · 21:53 UTCTHE HILL
    Moderna mRNA flu vaccine to get FDA panel review

    Moderna's experimental mRNA flu vaccine (MFLUSIVA) will undergo FDA advisory panel review on June 18. This development follows the departure of former FDA head Marty Makary and signals a return to more stable regulatory processes for drug reviews.